Mesoblast faces FDA pushback over cell therapy manufacturing, clinical data: documents

The FDA in recent years has been tough on cell and gene therapy makers, particularly when its comes to approving the labor-intensive and complicated manufacturing process. The agency now has its eyes set on Mesoblast's cell therapy candidate—and an early review doesn't look positive.